Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
10,154
archived clinical trials in
Other Indications

A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Phoenix, AZ
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Long Beach, CA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Sacramento, CA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Aurora, CO
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Washington,
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Decatur, GA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Chicago, IL
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Iowa City, IA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Louisville, KY
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Baltimore, MD
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Worcester, MA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
New York, NY
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Staten Island, NY
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Durham, NC
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Media, PA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Media, PA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Houston, TX
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Seattle, WA
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated:  9/1/2015
Research Site
mi
from
Bahía Blanca,
A Study of RO4917523 in Patients With Fragile X Syndrome
A Randomized, Double-blind, 12-week, Parallel Group, Placebo-controlled Study of Efficacy and Safety of RO4917523 in Patients With Fragile X Syndrome.
Status: Enrolling
Updated: 9/1/2015
Research Site
mi
from
Bahía Blanca,
Click here to add this to my saved trials
Computer Decision Support to Achieve Glycemic Control in the ICU
Computer Decision Support to Achieve Glycemic Control in the ICU
Status: Enrolling
Updated:  9/1/2015
U.S. Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Computer Decision Support to Achieve Glycemic Control in the ICU
Computer Decision Support to Achieve Glycemic Control in the ICU
Status: Enrolling
Updated: 9/1/2015
U.S. Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
The Effects Grapes on Health Indices
Pilot Study: The Effects of Whole Grapes on Markers of Health
Status: Enrolling
Updated:  9/3/2015
Ragle Human Nutrition Center
mi
from
Davis, CA
The Effects Grapes on Health Indices
Pilot Study: The Effects of Whole Grapes on Markers of Health
Status: Enrolling
Updated: 9/3/2015
Ragle Human Nutrition Center
mi
from
Davis, CA
Click here to add this to my saved trials
Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds
Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds
Status: Enrolling
Updated:  9/8/2015
US Army Institute of Surgical Research, Burn Center
mi
from
Ft. Sam Houston, TX
Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds
Evaluation of Oxygen Diffusion Dressing for Accelerating Healing of Donor Site and Other Wounds
Status: Enrolling
Updated: 9/8/2015
US Army Institute of Surgical Research, Burn Center
mi
from
Ft. Sam Houston, TX
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Anaheim/Orange County
mi
from
Anaheim, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Baldwin Park
mi
from
Baldwin Park, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Bellflower
mi
from
Bellflower, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Bellflower
mi
from
Bellflower, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Fontana
mi
from
Fontana, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Fontana
mi
from
Fontana, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Harbor City
mi
from
Harbor City, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Harbor City
mi
from
Harbor City, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Hayward
mi
from
Hayward, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Foundation Hospital - West Los Angeles
mi
from
Los Angeles, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Foundation Hospital - West Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
mi
from
Ontario, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente - Ontario Vineyard Medical Offices and Ambulatory SurgiCenter
mi
from
Ontario, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Riverside
mi
from
Riverside, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Riverside
mi
from
Riverside, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
South Sacramento Kaiser-Permanente Medical Center
mi
from
Sacramento, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
South Sacramento Kaiser-Permanente Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Sacramento
mi
from
Sacramento, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego
mi
from
San Diego, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Kaiser Foundation Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - San Francisco Geary Campus
mi
from
San Francisco, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - San Francisco Geary Campus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Santa Teresa
mi
from
San Jose, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Santa Teresa
mi
from
San Jose, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Health Care
mi
from
San Marcos, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Health Care
mi
from
San Marcos, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Foundation Hospital - San Rafael
mi
from
San Rafael, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Foundation Hospital - San Rafael
mi
from
San Rafael, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - Santa Rosa
mi
from
Santa Rosa, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - Santa Rosa
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated:  9/8/2015
Kaiser Permanente Medical Center - South San Francisco
mi
from
South San Francisco, CA
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32
Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Status: Enrolling
Updated: 9/8/2015
Kaiser Permanente Medical Center - South San Francisco
mi
from
South San Francisco, CA
Click here to add this to my saved trials